Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06734585
A Study of Real-world Treatment of Adults With Urothelial Cancer in South Korea and Saudi Arabia
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT06505746
- Locations
- 🇰🇷
KR00001, Seoul, Korea, Republic of
A Survey Evaluating Prevalence, Severity and Associated Factors in East Asian Women With Moderate-to-severe Menopause-related Vasomotor Symptoms (MR-VMS)
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 3399
- Registration Number
- NCT04553029
- Locations
- 🇨🇳
Site CN86002, Beijing, China
🇨🇳Site TW88601, Taipei, Taiwan
🇰🇷Site KR82001, Seoul, Korea, Republic of
A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 6295279
- Registration Number
- NCT03903094
- Locations
- 🇦🇺
Site AU61001, Melbourne, Australia
🇰🇷Site KR82001, Seoul, Korea, Republic of
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 5589
- Registration Number
- NCT03602508
- Locations
- 🇦🇺
Site AU10000, Sydney, Australia
🇰🇷Site KR82001, Seoul, Korea, Republic of
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 805
- Registration Number
- NCT03572231
- Locations
- 🇰🇷
Site KR410008, Daejeon, Korea, Republic of
🇰🇷Site KR410009, Incheon, Korea, Republic of
🇰🇷Site KR410005, Kangam, Korea, Republic of
Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT03174457
- Locations
- 🇨🇳
Site TW601, Taipei, Taiwan
🇨🇳Site TW604, Taipei, Taiwan
🇰🇷Site KR401, Seoul, Korea, Republic of
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT03035032
- Locations
- 🇲🇾
Site MY03002, Batu Caves, Selangor, Malaysia
🇵ðŸ‡Site PH04001, Makati City, Metro Manila, Philippines
🇵ðŸ‡Site PH04003, Manila, Metro Manila, Philippines
A Cross-sectional Internet Survey to Estimate Prevalence of Lower Urinary Tract Symptoms (LUTS)
Completed
- Conditions
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 8284
- Registration Number
- NCT02618421
© Copyright 2024. All Rights Reserved by MedPath